Opinion|Videos|November 12, 2024
Clinical Pearls for Management of Generalized Myasthenia Gravis
Key Takeaways
- Multidisciplinary collaboration is essential for managing the complex needs of gMG patients, involving neurologists, pediatricians, cardiologists, and other specialists.
- Continuous education and awareness of the latest treatment options and management strategies are crucial for improving patient outcomes in gMG.
Panelists discuss how a multidisciplinary approach involving various specialists is crucial in managing generalized myasthenia gravis (gMG), offering final insights and recommendations for health care professionals treating gMG patients.
Advertisement
Video content above is prompted by the following:
- Care for patients with gMG involves neurologists, pediatricians, cardiologists, and other specialists. Please share your final thoughts and advice with the medical community working to treat patients with gMG.
Advertisement
Related to this article
As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
At a NeurologyLive Clinical Forum in Philadelphia, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
3
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
4
Headlining Current Advances and Challenges in Multiple Sclerosis Care
5